\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationNaples
ProgrammesThe 10th FIWARE Global Summit, an Open Source conference for entrepreneurs, public administrations, academia, developers, start-ups, and technologists, will take place in Naples, Italy on 18-19 September 2024.
To find out more about the programme and to register, please visit the conference website.
Please note that this is a paying event.
FIWARE is a curated framwork of open-source platform components designed to facilitate the development of smart applications across various sectors, such as smart cities, industry, and agriculture. It provides a set of standardized APIs and data models, enabling seamless integration and interoperability between different systems and applications.
FIWARE's catalogue includes a diverse range of Generic Enablers—modular building blocks covering areas like data processing, IoT, security, and big data analysis. By leveraging these enablers, developers can accelerate the creation of innovative solutions, ensuring they are scalable, secure, and future-proof. Its open-source nature encourages collaboration and reduces development costs, fostering a vibrant community and widespread adoption.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
